Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aziyo Biologics (ELUT)
NASDAQ:ELUT
Holding ELUT?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.25Last Year’s EPS
-$0.66Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: 26.37%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view, with significant achievements in the introduction and adoption of the EluPro product line and growth in the SimpliDerm segment. However, there were also challenges, including a slight decrease in sales and increased operating expenses. The overall sentiment is cautiously optimistic about future growth.Company Guidance
During the Elutia Third Quarter 2024 Earnings Call, the guidance provided highlighted several key metrics and strategic initiatives. The company reported a revenue of $5.9 million for the quarter, a slight decline from $6.1 million in the same period last year. SimpliDerm sales demonstrated robust growth with a 19% increase, contributing $3.1 million. The adjusted gross margin improved to 61% from the previous year's 60%, with the bioenvelope business, including EluPro and CanGaroo, achieving a 68% gross margin. The company emphasized its strategic focus on the upcoming commercial launch of EluPro in January 2025, following its initial implant in September 2024. EluPro is already accounting for 25% of bio envelope sales and is being adopted across all major CIED brands. The company also noted its expansion efforts in sales, with a current mix of 12 direct reps and 34 independent reps, alongside nine product consultants. Furthermore, Elutia ended the quarter with $25.7 million in cash, bolstered by warrant exercises amounting to an additional $13.8 million. The net income was a positive $1.3 million, largely due to noncash gains from warrant revaluation, while the adjusted EBITDA loss stood at $2.9 million. Overall, the company expressed strong enthusiasm for its strategic and financial positioning, particularly with the EluPro rollout and ongoing business development discussions.EluPro Product Line Introduction
The EluPro product line was introduced, with the first implant in September and commercial launch planned for January 2025. It accounts for 25% of bio envelope sales and is being used across all major CIED brands.
SimpliDerm Growth
SimpliDerm product line in breast reconstruction grew by 19% this quarter, returning to a more normal growth rate.
Expansion of Commercial Footprint
Significant key additions to Southern California and the Northeast with a hybrid model of 12 direct reps, 34 independent reps, and 9 product consultants.
Positive Net Income
The company reported a positive net income of $1.3 million for the quarter, primarily due to a noncash gain from warrant revaluation.
Peer-Reviewed Publication and Clinical Study
Published data showcasing EluPro's effectiveness in eliminating key bacterial contaminants and initiated a clinical study to provide real-world outcomes data.
---
ELUT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ELUT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $3.83 | $3.56 | -7.05% |
| Aug 07, 2024 | $2.84 | $3.07 | +8.10% |
| May 09, 2024 | $2.80 | $3.29 | +17.50% |
| Mar 07, 2024 | $3.59 | $3.24 | -9.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aziyo Biologics (ELUT) report earnings?
Aziyo Biologics (ELUT) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Aziyo Biologics (ELUT) earnings time?
Aziyo Biologics (ELUT) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELUT EPS forecast?
ELUT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.25.
---